Inve US ▾
MEMED

Medifast (MED) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Consumer Discretionary· Aug 3, 2026

Source: earnings call transcript

Executive summary

Medifast Q2 FY26 — Strategic Shift to Metabolic Health with Trilivi Launch

Medifast is undergoing a significant strategic transition, launching its new Trilivi brand and 3.0 strategy focused on comprehensive metabolic health. Despite a decline in active coaches and revenue, the company reported strong coach productivity and met its Q2 revenue and earnings expectations. Management is focused on returning to profitability by Q4 2026 through cost-saving initiatives and the new product line, leveraging its strong balance sheet and scientific heritage.

Highlights

4

  • Active earning coach productivity up 41% YoY and 20% sequentially, reaching highest level since Q2 2022.

  • Ended the quarter with $169.8 million in cash and investments and no debt, maintaining a strong balance sheet.

  • Q2 revenue of $76 million met guidance, reflecting positive operating indicators and improved client retention.

  • Enhanced compensation plan launched August 1st to accelerate growth by focusing on Executive Directors, who remain over the 10% benchmark.

Concerns

4

  • Revenue decreased 27.6% YoY to $76.4 million, primarily due to a decline in active earning coaches.

  • Active earning coach count decreased 48.7% YoY to approximately 11,700.

  • Gross profit decreased 30.3% YoY to $53.4 million, with gross profit margin declining to 69.9% from 72.6% due to loss of leverage on fixed costs.

  • Net loss of $3.1 million, or $0.28 per diluted share, compared to net income of $2.5 million, or $0.22 per share, in the prior year.

Guidance & targets

CategoryTargetConfidence
Q3 FY26 Revenue
$60 million to $80 million
high materiality
High
Q3 FY26 Loss Per Share
$0.15 to $0.65
high materiality
High
Full-Year FY26 Revenue
$270 million to $300 million
high materiality
High
Full-Year FY26 Loss Per Share
$0.25 to $1.75
high materiality
High
Return to Profitability
Q4 2026
high materiality
High
Working Capital
>$145 million
medium materiality
High
Coach Productivity Growth
continued growth
medium materiality
High
Earnings Improvement
continue into 2027 and beyond
medium materiality
Medium

Product announcements

ProductTypeDetails
Trilivilaunch
Medifast Metabolic Health Institutelaunch
Reset Fuelings (Medivantage Technology)launch

Risks & headwinds

Decline in Active Earning Coaches Q2 FY26

down 48.7% YoY to 11,700

Mitigation:Enhanced compensation plan, focus on Executive Directors, new brand launch (Trilivi) and product offerings to drive coach engagement and growth.

Loss of Leverage on Fixed Costs Q2 FY26

Gross profit margin decreased from 72.6% to 69.9% (270 bps impact on SG&A as % of revenue)

Mitigation:Catalyst program for cost savings and efficiency, expected stabilization and growth of the business into 2027 to improve leverage.

Initial Costs of Catalyst Program Q3 FY26

One-time costs (not yet quantified)

Mitigation:These costs are excluded from Q3 EPS guidance and will be called out in Q3 earnings. Expected to lead to 'millions of savings' in the long term.

Market Understanding of Metabolic Health current

80% of adults do not understand what metabolic health means

Mitigation:Medifast Metabolic Health Institute to provide evidence-based education and establish the company as a trusted authority; coach-guided system to close the understanding gap.

What to watch in Q3 FY26

Catalyst Program Savings Quantification

Q3 FY26 earnings call
Current millions of savings (unquantified)
Target quantified savings details

Why it matters

Quantification of Catalyst program savings is crucial for assessing the company's path to profitability and the effectiveness of its cost-reduction efforts.

What we can say now is we believe there's millions of savings, millions of dollars of savings, but we're not able to quantify it because we're actually working through what we plan to reduce. [...] We are going to be doing that in our Q3 earnings call.

Find out whether MED delivers this. Inve re-checks your case every morning.

Q&A highlights

Analyst inquired about the initial implementation costs, expected savings, and cadence of the Catalyst Program, and whether it's the sole driver for Q4 2026 profitability or if other factors like top-line recovery and new product launches contribute.

Management stated that specific quantification of Catalyst program savings would be provided in the Q3 earnings call, but confirmed it involves 'millions of savings' focused on simplifying the business without impacting top-line revenue. They clarified that Q4 profitability is also supported by the new product line launch and stabilization of the top line, noting that the full-year EPS range has improved.

“What we can say now is we believe there's millions of savings, millions of dollars of savings, but we're not able to quantify it because we're actually working through what we plan to reduce.”

asked by James Salera · answered by Unknown Speaker

2 min read 5 chapters

Detailed narrative

Strategic Shift to Metabolic Health with Trilivi

Medifast is executing its 3.0 strategy, marking the biggest shift since Optivia's 2017 launch. This 10-year roadmap aims to expand offerings to coaches and clients within a comprehensive metabolic health system, broadening geographic and demographic footprints. The new consumer brand, Trilivi, replaces Optivia, reflecting a holistic health approach beyond just weight loss, focusing on metabolic reset through three phases: reset, refine, and renew.

This strategy is underpinned by speed, simplicity, scale, and stewardship.

Metabolic Health Institute and Science-Backed Products

The company launched the Medifast Metabolic Health Institute in July, dedicated to advancing metabolic health through research and evidence-based education. This institute, led by experts with over 390 years of collective experience, aims to strengthen the evidence base for programs and establish Medifast as a trusted authority.

Concurrently, new Reset Fuelings, utilizing proprietary Medivantage Technology, are launching later this month. These fuelings are designed to support normal fat metabolism, healthy insulin function, and reduced waist circumference, anchoring the clinically proven Reset 5-in-1 Plan.

Coach Engagement and Compensation Enhancements

Despite a decline in the overall number of coaches, active earning coach productivity has shown positive trends for the third consecutive quarter, up 41% YoY and 20% sequentially. Revenue per active earning coach is at its highest since Q2 2022.

An enhanced compensation plan launched on August 1st aims to further accelerate growth by focusing on developing Executive Directors, who are key drivers of sustainable growth and remain above the 10% benchmark for a healthy field organization. The client referral program also continues to exceed expectations.

Catalyst Program for Cost Savings and Profitability

Medifast initiated its Catalyst program in Q2, with the majority of execution expected in Q3. This program targets additional cost savings through facility rationalization, AI-related efficiencies, and other means, without impacting growth capabilities. The Catalyst program is a key component in the company's objective to return to profitability by Q4 2026, with further earnings improvements targeted for 2027 and beyond.

Management expects to share more quantified details on savings in the Q3 earnings call.

Market Opportunity and GLP-1 Engagement

The company highlights a significant market opportunity, noting that over 90% of US adults and 1.5 billion worldwide are metabolically unhealthy, yet 80% lack understanding of metabolic health. Medifast's coach-guided system aims to bridge this gap. The company continues to engage with the GLP-1 market, supporting individuals whether they are using medication, coming off it, or pursuing non-medication pathways, emphasizing holistic lifestyle change and behavioral modification.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.